GRANTS,
N.M., March 7, 2024 – PRESS RELEASE – Bright Green Corp., a Delaware
corporation, announced the submission of its Drug Enforcement Administration (DEA)
registration for bulk production of Schedule I and Schedule II controlled substances.
The
application is an official and substantial step in Bright Green's expansion
into the legal manufacturing of plant-based controlled substances, including
psilocybin, peyote, ibogaine, coca leaves, and opium poppy, alongside their
active pharmaceutical ingredients (API) for medical, research, and other legal
purposes. The move aligns with Bright Green's commitment to providing a
domestic supply of essential medications, addressing critical concerns
associated with disruptions to the global pharmaceutical supply chain, and the
national security risk currently posed by the United States’ dependency on
imports.
Last
year, Bright Green obtained its DEA registration for the bulk manufacturing of cannabis,
a Schedule I controlled substance, and recently received approval from the New
Mexico Board of Pharmacy to produce additional Schedule I and Schedule II controlled
substances. In response to these approvals already in place, Bright Green has
undergone substantial renovations and expansions at its Grants, N.M., facility
to support this new era of operations.
"Our
vision is to play a vital role in production, storage and supply of plant and
fungi-based controlled substances domestically to secure and continue the plan
for ‘Drugs Made in America,’” Bright Green CEO Groovy Singh said. "Through
continued rigorous compliance with federal, state, and local regulations, we
aim to contribute to the advancement of medical research and alleviate the
impact of chronic diseases affecting a significant portion of the U.S.
population."
Bright
Green's application demonstrates its dedication to meeting the public interest
factors outlined by 21 U.S.C. § 823(a), including effective diversion control,
compliance with laws, promotion of technical advances, and a commitment to
public health and safety. The company has assembled a team of experienced
professionals to lead its controlled substance production efforts, ensuring
adherence to stringent security and compliance standards.
The
submission of this registration marks a significant milestone for Bright Green
Corp. as it pioneers the “Drugs Made in America” movement. The company looks
forward to collaborating with the DEA and the state of New Mexico to facilitate
the safe and responsible production and distribution of medications to meet
rapidly growing demand.
